Document is current
Any future updates will be listed below
-
Authors
Stanchina, Michele D. https://orcid.org/0000-0002-4691-7645
Montoya, Skye
Danilov, Alexey V.
Castillo, Jorge J. https://orcid.org/0000-0001-9490-7532
Alencar, Alvaro J.
Chavez, Julio C.
Cheah, Chan Y. https://orcid.org/0000-0001-7988-1565
Chiattone, Carlos
Wang, Yucai
Thompson, Meghan
Ghia, Paolo https://orcid.org/0000-0003-3750-7342
Taylor, Justin https://orcid.org/0000-0003-4407-6325
Alderuccio, Juan Pablo https://orcid.org/0000-0002-2690-3377
- License Information
-
More Information
Article History
Accepted: 2 October 2024
First Online: 1 November 2024
Competing interests
: A.V.D. has received research funding and consultancy fees from Abbvie, AstraZeneca, Beigene, Bristol Myers Squibb, GenMab, Lilly Oncology, MEI Pharma, Nurix Therapeutics and Presage; research funding from Bayer, Cyclacel and Incyte; and consultancy fees from Genentech, Janssen, Merck and Regeneron. J.J.C. reports consulting or advisory roles for AbbVie/Pharmacyclics, BeiGene, Cellectar, Janssen, Kite Pharma/Gilead, Loxo Oncology/Lilly, Mustang Bio and Roche/Genentech, and institutional research funding from AbbVie, AstraZeneca, BeiGene, Cellectar, Loxo/Lilly, Pharmacyclics and TG Therapeutics. A.J.A. has received consultancy fees from Amgen, BeiGene, Epizyme, Genentech, Incyte, Janssen, Kite, Lilly, Seagen, and TG Therapeutics and research funding from BeiGene, Incyte and Loxo Oncology. J.C.C. has received consultancy fees from AbbVie, ADC Therapeutics, Adicet, AstraZeneca, BeiGene, Bristol Myers Squibb, Cellectar, Genentech, Genmab, Janssen, Kite Pharma/Gilead and Novartis; honoraria from AstraZeneca, BeiGene and Lilly; research funding from AstraZeneca, Janssen and Merck; and has served as a Data and Safety Monitoring Board member for Atara and the National Cancer Institute. C.Y.C. has received consultancy fees or honoraria from AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Dizal, Genmab, Gilead, Janssen, Lilly, Menarini, Novartis, Roche, and TG Therapeutics and research funding from AbbVie, Bristol Myers Squibb, Lilly, MSD and Roche. Y.W. has received institutional research funding from Genentech, Genmab, Incyte, InnoCare, Lilly, Loxo Oncology, MorphoSys, and Novartis and institutional honoraria from Kite Pharma; has served on advisory boards (compensation to institution) for AstraZeneca, BeiGene, Incyte, InnoCare, Jansen, Kite Pharma/Gilead, Lilly, Loxo Oncology and TG Therapeutics; has consulted for (compensation to institution) AbbVie and Innocare; and has an immediate family member who is employed by and has stock ownership in Merck. M.T. has received consultancy fees from AstraZeneca, Loxo Oncology/Lilly and Pharmacyclics/Janssen; honoraria from the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy, Curio Science, Dava Oncology, Intellisphere, the Massachusetts Medical Society, MJH Life Sciences, and VJHemOnc and institutional research funding from Abbvie, AstraZeneca, Beigene, Genentech, Genmab and Nurix Therapeutics. P.G. has received honoraria from AbbVie, ArQule/MSD, AstraZeneca, BeiGene, Celgene/Juno/Bristol Myers Squibb, Janssen, Loxo Oncology/Lilly, MEI Pharma, Roche, and Sanofi and research funding from AbbVie, AstraZeneca, Bristol Myers Squibb, Janssen and Sunesis. J.P.A. has received consultancy fees from AbbVie, ADC Therapeutics, Genentech, and Regeneron and research funding from AbbVie, ADC Therapeutics, BeiGene and Genmab. M.D.S., S.M., C.C. and J.T. declare no competing interests.
